Will We Ever See An Anti-Aging Drug Hit The Market?
The $260-billion Swiss company has a long way to go until rapamycin hits the shelves as an anti-aging drug. One big problem Novartis faces is that the FDA does not consider aging to be a disease. Therefore, it is unlikely to approve a drug that “treats” aging. Additionally, the FDA has historically required extremely high safety standards in any drug meant to treat healthy people.
Novartis is moving slowly with rapamycin, focusing the drug for specific medical conditions. Will we see rapamycin available as a general anti-aging drug in the future? Only time will tell.
At Aesthetika, Dr. Castaneda has been helping people with anti-aging dental treatments for 25 years!